tarcocimab tedromer

Tarcocimab tedromer is an investigational antibody biopolymer conjugate (ABC) developed by Kodiak Sciences for the treatment of retinal vascular diseases. It is a novel anti-VEGF biologic designed to provide both strong immediacy and high durability in VEGF inhibition, aiming to reduce treatment burden with extended dosing intervals of up to six months. The drug consists of an anti-VEGF monoclonal antibody conjugated to a biopolymer, which extends its duration of effect within the retina. Tarcocimab tedromer has been evaluated in multiple phase 3 clinical trials for indications including diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and neovascular (wet) age-related macular degeneration[2][3][5]. While it demonstrated efficacy and safety in several studies—such as significant improvements in diabetic retinopathy severity scores—it did not meet all primary endpoints compared to standard-of-care agents like aflibercept in some trials[10]. The drug is administered via intravitreal injection.

Brand names

Zenkuda

Other names

KSI-301KSI301KSI 301tarcocimab tedromer